生物制剂在SAPHO综合征的治疗

摘要

SAPHO综合征是罕见病，具有显著炎性皮肤和骨关节表现。关于本病的治疗多参照血清阴性脊柱关节病，生物制剂近10年也有应用于本病的报道。肿瘤坏死因子α（ tumor necrosis factor-α， TNF-α）拮抗剂通常用于治疗对常规治疗无应答的患者，证明对骨关节有显著疗效。近期白细胞介素（ interleukin， IL）-1单抗也证实治疗有效，目前认为Th17相关信号通路可能参与本病，乌司努单抗也有个案报道， IL-17单抗在银屑病关节炎取得良好效果，有望用于本病的治疗。%SAPHO syndrome is a rare disease presented with dermatitis, osteitis and arthritis.The treatment for SAPHO syndrome traditionally follows that of seronegative spondyloarthropathy.Biological agents have been used as a new therapy for seronegative spondyoarthropathy in recent 10 years.Tumor necrosis factor-α( TNF-α) blockers has been proposed to be effective in patients who are non-responders to standard treatment.Recently, Interleukin-1 (IL-1) blockers and Ustekinumab were also reported to be effective in SAPHO syndrome.On the other hand, since TH17 related pathway may be involved in the pathophysiological process of SAPHO syndrome, IL-17 blocker has been proposed to be a potential therapy, which has been tested to be effective in psoriatic arthritis, therefore, it may be a possible new therapy for SAPHO syndrome.